Abbvie Inc. · NYSE:ABBV

Abbvie — Q4 2021 Earnings Presentation

4 slides from Abbvie's earnings presentation, Feb 2, 2022

  1. Slide 1: AbbVie Pipeline Update

    AbbVie Pipeline Update February 2, 2022

  2. Slide 2: AbbVie R&D Pipeline

    AbbVie R&D Pipeline Phase 1 Phase 2 Registrational / Phase 3 Submitted ■ ABBV-668 (RIPK1) Multiple Immunology ■ ABBV-154 (TNF-Steroid ADC) RA ■ Rinvoq (JAK 1) CD ■ Rinvoq (JAK 1) AS (US) Diseases ■ ABBV-154 (TNF-Steroid ADC) PMR ■ Rinvoq (JAK 1) GCA ■ Rinvoq (JAK 1) UC ■ ABBV-151 (GARP+TGFb1) Solid

  3. Slide 3: Anticipated Key Pipeline Events

    Anticipated Key Pipeline Events 2022 2023 Regulatory Rinvoq AD (US) Skyrizi PsA (US) Rinvoq CD Navitoclax 1L and R/R MF Rinvoq AS (US) Imbruvica + Venclexta 1L CLL Imbruvica + Venclexta R/R MCL Epcoritamab 3L R/R DLBCL (AA) Approvals Rinvoq UC Venclexta Higher Risk MDS (AA) Imbruvica R/R FL/MZL ABBV

  4. Slide 4: AbbVie's Partnered Assets

    AbbVie’s Partnered Assets • Imbruvica jointly developed with Janssen Biotech • Venclexta jointly developed with Roche • Skyrizi developed in cooperation with Boehringer Ingelheim • Vraylar developed in cooperation with Gedeon Richter • ABBV-0805 developed in cooperation with BioArctic • CCW702 devel

AbbVie — Q4 2021 Earnings Presentation on 6ix